• HyperPFU™ high-fidelity DNA polymerase: Technical Use Guide

  2026-07-19

  HyperPFU™ high-fidelity DNA polymerase addresses the technical challenges of amplifying long, GC-rich, or otherwise difficult DNA templates with high fidelity and speed. It is ideal for workflows requiring blunt-ended, accurate PCR products, such as cloning and high-throughput sequencing, but should not be used when 3'-A overhangs or sticky ends are necessary.

• Enabling mRNA-Based Tumor Suppressor Therapy: ATP Solution i

  2026-07-18

  This article unpacks the mechanistic and strategic value of high-purity ATP Solution (100 mM) in the development and optimization of mRNA-based tumor suppressor therapies for bladder cancer. Drawing on recent advances in lipid nanoparticle-mediated p21 mRNA delivery, we bridge cutting-edge biological rationale with actionable guidance for translational researchers, highlighting how APExBIO’s ATP Solution enables reproducibility and precision in sensitive kinase, transcription, and phosphorylation workflows critical to next-generation cancer therapeutics.

• Q-VD-OPh: Pan-Caspase Inhibitor Workflows for Apoptosis Rese

  2026-07-17

  Q-VD-OPh empowers researchers to dissect apoptosis mechanisms with precision, offering robust caspase inhibition in both in vitro and in vivo systems. Its cell-permeable, irreversible action not only advances fundamental studies but also improves viability in sensitive applications like cryopreservation and neurodegenerative modeling.

• Docetaxel in Cancer Chemotherapy Research: Applied Workflows

  2026-07-17

  Docetaxel (Taxotere) sets a gold-standard in cancer chemotherapy research, enabling precise apoptosis induction and chemoresistance studies across breast, ovarian, and gastric cancer models. This article delivers advanced workflow guidance, troubleshooting insights, and actionable protocol parameters, translating recent gene network findings into bench-ready strategies.

• Yeast-Engineered Exendin-4: Expanding Access to Diabetes Res

  2026-07-16

  This study demonstrates stable chromosomal expression of Exendin-4 in Saccharomyces cerevisiae, enabling cost-effective, scalable production of a key GLP-1 receptor agonist for type 2 diabetes research. The platform addresses critical barriers to medication accessibility and lays groundwork for both local manufacturing and novel research workflows.

• T7 RNA Polymerase: Strategic Leverage for Translational RNA

  2026-07-16

  Explore the strategic and mechanistic role of T7 RNA Polymerase—a recombinant enzyme expressed in E. coli—in advancing translational RNA research, with actionable guidance for researchers designing in vitro transcription, RNA vaccine production, and RNAi workflows. This thought-leadership article bridges molecular insight with translational opportunity, contextualizing APExBIO’s T7 RNA Polymerase within the current landscape and referencing landmark studies to inform best practices.

• Lovastatin as an HMG-CoA Reductase Inhibitor: Applied Protoc

  2026-07-15

  Lovastatin’s nanomolar potency as an HMG-CoA reductase inhibitor makes it a trusted tool for probing cholesterol metabolism, apoptosis, and cancer cell biology. This article translates current research and product guidance into actionable protocols, troubleshooting strategies, and comparative insights for advanced laboratory workflows.

• Inducing Right Ventricular Cardiomyocytes from Human PSCs

  2026-07-15

  Saito et al. present a modified differentiation protocol enabling specific induction of right ventricular-like cardiomyocytes from human pluripotent stem cells. This advance provides a foundation for chamber-specific cardiac disease modeling and drug testing, addressing a significant gap in translational cardiac research.

• Collagen VI-Enhanced ECM Scaffolds Advance Islet Organoid Ma

  2026-07-14

  This study demonstrates that decellularized amniotic membrane (dAM) hydrogels enriched with collagen VI significantly promote the viability, architectural fidelity, and functional maturation of iPSC-derived islet organoids. These findings offer a robust platform for improving diabetes cell therapy and provide insight into extracellular matrix optimization for organoid engineering.

• Bay 11-7821: Strategic Leverage in Inflammation and Cancer R

  2026-07-14

  This article explores how Bay 11-7821 (BAY 11-7082) revolutionizes inflammatory signaling pathway research and apoptosis regulation studies. By integrating fresh mechanistic insights—such as lactate-driven HMGB1 release in sepsis—with translational strategy, we provide actionable guidance for researchers aiming to push the boundaries of cancer, immunology, and inflammation models. The discussion amplifies beyond standard product profiles, contextualizing APExBIO’s Bay 11-7821 as a tool for next-generation discoveries.

• Workflow Guide: HyperPFU™ High-Fidelity DNA Polymerase (K103

  2026-07-13

  HyperPFU™ high-fidelity DNA polymerase addresses the challenge of amplifying long, difficult, or GC-rich templates where standard PCR enzymes often fail due to low fidelity or limited processivity. It is well-suited for workflows demanding blunt-ended, high-accuracy PCR products, but is not appropriate for protocols requiring 3'-A overhangs or sticky-end generation.

• Calpain Inhibition Restores Offspring Cognition Post-Materna

  2026-07-13

  This study elucidates how excessive calpain activation, triggered by maternal non-obstetric surgery during pregnancy, disrupts BDNF/TrkB-mediated hippocampal development and impairs offspring cognition. Pharmacological inhibition with MDL 28170 partially reverses these effects, highlighting a targeted neuroprotection strategy for perinatal brain injury.

• RP3-340N1.2 Knockdown Destabilizes IL-6 and Limits NSCLC Pro

  2026-07-12

  This study demonstrates that the long non-coding RNA RP3-340N1.2 promotes non-small cell lung cancer (NSCLC) progression by stabilizing IL-6 mRNA. Knockdown of RP3-340N1.2 enhances IL-6 mRNA degradation, suppressing tumor cell proliferation and migration, and provides mechanistic insight for transcriptional regulation research.

• Lymphodepleting Chemotherapy Enhances Neoantigen T Cell Ther

  2026-07-10

  This study uncovers how lymphodepleting chemotherapy, specifically cyclophosphamide and fludarabine, remodels the tumor antigenic landscape to enhance the efficacy of neoantigen-directed adoptive T cell therapy. By increasing immunoproteasome activity and HLA-I expression, chemotherapy synergizes with engineered T cells to improve tumor cell recognition and killing, offering new mechanistic insights for optimizing immunotherapy in solid tumors.

• Cefepime (BMY-28142): Optimizing CNS Infection Research Work

  2026-07-09

  Cefepime (BMY-28142) stands out for its potent blood-brain barrier penetration and broad-spectrum antimicrobial activity, enabling rigorous central nervous system infection models. This article delivers practical protocol enhancements, troubleshooting insights, and evidence-based strategies to advance research on Gram-positive and Gram-negative pathogens.

8780 records 6/586 page Previous Next First page 上5页 678910 下5页 Last page